Cannara Biotech Reports Record Q3 Revenue and Accelerates Capacity Expansion
Event summary
- Cannara Biotech reported Q3 2026 revenues of $31.8 million, up 16% year-over-year.
- Gross profit before fair value adjustments was $13.4 million, or 42% of revenues.
- Activated two additional grow zones at the Valleyfield facility, increasing annualized production capacity to over 58,000 kg.
- Secured exclusive Canadian rights to Blue River’s Ampersand™ live rosin infusion technology.
- Entered a long-term international supply agreement with Curaleaf for bulk cannabis flower.
The big picture
Cannara Biotech's strong Q3 performance underscores its strategic focus on expanding production capacity and securing key partnerships. The company's ability to maintain profitability while scaling operations positions it favorably in the competitive Canadian cannabis market. The long-term supply agreement with Curaleaf signals potential for international growth, though execution risks remain.
What we're watching
- Market Expansion
- Whether Cannara can sustain its market share growth in Ontario and Alberta while expanding nationally.
- Capacity Utilization
- The pace at which Cannara activates additional grow zones and reaches its targeted capacity of 75,000 kg annually.
- Product Innovation
- How the launch of Ampersand™ products under the Nugz brand will impact sales and market positioning.